An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Geron Corporation (GERN) CEO to participate in fireside chat at B. Riley Securities Virtual Oncology Conference
Positive
None.
Negative
None.
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18th, 2024, at 10:30am ET.
A webcast of the presentation will be available through the Investors and Media section of Geron’s website under Events following the presentation. The webcast will be archived and available for replay for a period of 30 days.
About Geron
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application (NDA) for imetelstat in lower risk myelodysplastic syndromes (LR MDS), based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024. Additionally, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (MF). To learn more, visit www.geron.com or follow us on LinkedIn.
When and where is John A. Scarlett, M.D., Geron’s Chairman and CEO participating in a fireside chat?
John A. Scarlett, M.D., Geron’s Chairman and CEO is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18th, 2024, at 10:30am ET.
Where can I watch the webcast of the presentation?
A webcast of the presentation will be available through the Investors and Media section of Geron’s website under Events following the presentation.
Will the webcast be available for replay?
Yes, the webcast will be archived and available for replay for a period of 30 days.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.